Raf kinase inhibitory protein (RKIP), also termed PEBP1, is a modulator of regulatory kinase pathways in mammalian cells that control cell growth, motility, invasion, cell survival, chromosomal integrity, and drug resistance. Dysregulation of RKIP can disrupt normal homeostatic processes and result in a number of diseases including metastatic cancer, [1] [2] [3] asthma, 4 systemic inflammatory response syndrome, 5 Alzheimer's, 6 and heart disease. 7 Thus, understanding mechanisms regulating RKIP function could have an important impact on treatment of various disease states. RKIP has potential utility both as a direct biological target and as an effective tool to elucidate other therapeutic targets, particularly for cancer treatment.
The function of RKIP is highly dependent on its unique structure. RKIP is a member of the phosphatidylethanolamine-binding protein (PEBP) family that is evolutionarily conserved in structure as well as sequence within over 400 species from bacteria to man. [8] [9] [10] RKIP is a 21 kDa protein composed of a single globular domain. Like other PEBPs, RKIP is characterized by a conserved pocket composed of a flexible loop that non-covalently interacts with the C-terminal α helix. However, unlike SH2-containing proteins, binding of RKIP to its targets is not simply a function of direct pocket interactions. 10 RKIP can be phosphorylated at multiple sites 10 but phosphorylation at residue S153 by protein kinase C (PKC) ultimately triggers a change in RKIP function. 7, 11 Specifically, S153 phosphorylation releases RKIP from inhibiting the Raf/MAP kinase pathway and promotes pRKIP inhibition of GRK2, upregulating the ß-adrenergic receptor signaling pathway. Thus, unlike many regulatory proteins that transition between simple on-off states, RKIP is an allosteric protein 10 that can assume more than one functional state, and there is no clear precedent for its structure-based mechanism of action.
RKIP fills a unique biological niche that has broad application but also poses new challenges. In addition to mechanistic issues, the affinity of RKIP for its targets as well as for kinases that phosphorylate RKIP as a substrate is relatively poor, making the elucidation of specifically interacting proteins difficult. 10 As a result, the study of RKIP and related PEBP family members is currently in its infancy. An analysis of papers published in this field over the past 10-15 years reveals a linear increase (Fig. 1) . Although the challenges inherent in studying RKIP and other PEBP family proteins have undoubtedly delayed rapid expansion of the field, recent development of new tools and models has made this field one of the most promising and exciting for understanding and treating diseases such as cancer.
The nature of these discoveries will be reviewed in the accompanying articles. Since this special issue focuses on RKIP and oncogenesis, the majority of the papers included will focus on the role of RKIP in cancer. These include a broad overview of the RKIP field (Article 1) as well as specific aspects of RKIP's role in cancer including its potential for elucidating effectors of metastatic progression and its potential utility for patient diagnosis, prognosis, and treatment (Articles 2-7). In addition, since RKIP activity is tightly controlled by its structure, Articles 8 and 9 address our current understanding of RKIP structure-function relations and present new models to explain RKIP action. Finally, the role of RKIP in regulating cardiac activity, asthma, and neural activity are addressed in Articles 8-10 to give insight into common mechanisms by which RKIP controls other physiological processes.
As befits an emerging field, the papers in this treatise must be considered a progress report. Different authors present distinct and sometimes contradictory interpretations of data and models to explain RKIP action. Since each author has often selected common aspects of RKIP biology to put their own work in perspective, some of the articles here will also overlap to a limited degree. These features were deliberately left so that each article can
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stand on its own as a complete review, but also so that the reader can gain a broader perspective on the state of the field and the nature of the questions that remain open. Key experiments are currently in progress in a number of laboratories that will undoubtedly resolve issues regarding the fundamental mechanism by which RKIP responds to signals and enables new translational applications of the insights we have gained.
Together, the work presented in this special volume represents the most comprehensive overview of RKIP and its role in oncogenesis to date. We anticipate that, as the key features of this fascinating protein family continue to be elucidated, we will see exponential growth in the RKIP field. The emerging role of RKIP loss in the pathology and biology of disease combined with increased understanding of mechanism should lead to a broad range of applications from new metastatic targets to novel therapeutic agents that will be the basis for ever widening interest in this multifaceted protein.
